226 related articles for article (PubMed ID: 28700899)
1. Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer.
Füredi A; Szebényi K; Tóth S; Cserepes M; Hámori L; Nagy V; Karai E; Vajdovich P; Imre T; Szabó P; Szüts D; Tóvári J; Szakács G
J Control Release; 2017 Sep; 261():287-296. PubMed ID: 28700899
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?
Mamidi RN; Weng S; Stellar S; Wang C; Yu N; Huang T; Tonelli AP; Kelley MF; Angiuoli A; Fung MC
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1173-84. PubMed ID: 20661737
[TBL] [Abstract][Full Text] [Related]
3. Investigation of Hexadecylphosphocholine (miltefosine) usage in Pegylated liposomal doxorubicin as a synergistic ingredient: In vitro and in vivo evaluation in mice bearing C26 colon carcinoma and B16F0 melanoma.
Teymouri M; Farzaneh H; Badiee A; Golmohammadzadeh S; Sadri K; Jaafari MR
Eur J Pharm Sci; 2015 Dec; 80():66-73. PubMed ID: 26299343
[TBL] [Abstract][Full Text] [Related]
4. Synergistic nanoparticulate drug combination overcomes multidrug resistance, increases efficacy, and reduces cardiotoxicity in a nonimmunocompromised breast tumor model.
Shuhendler AJ; Prasad P; Zhang RX; Amini MA; Sun M; Liu PP; Bristow RG; Rauth AM; Wu XY
Mol Pharm; 2014 Aug; 11(8):2659-74. PubMed ID: 24830351
[TBL] [Abstract][Full Text] [Related]
5. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model.
Zahmatkeshan M; Gheybi F; Rezayat SM; Jaafari MR
Eur J Pharm Sci; 2016 Apr; 86():125-35. PubMed ID: 26972276
[TBL] [Abstract][Full Text] [Related]
6. Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors.
Gazzano E; Rolando B; Chegaev K; Salaroglio IC; Kopecka J; Pedrini I; Saponara S; Sorge M; Buondonno I; Stella B; Marengo A; Valoti M; Brancaccio M; Fruttero R; Gasco A; Arpicco S; Riganti C
J Control Release; 2018 Jan; 270():37-52. PubMed ID: 29191785
[TBL] [Abstract][Full Text] [Related]
7. Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors.
Akhtari J; Rezayat SM; Teymouri M; Alavizadeh SH; Gheybi F; Badiee A; Jaafari MR
Int J Pharm; 2016 May; 505(1-2):89-95. PubMed ID: 27039149
[TBL] [Abstract][Full Text] [Related]
8. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
[TBL] [Abstract][Full Text] [Related]
9. Lipid bubbles combined with low-intensity ultrasound enhance the intratumoral accumulation and antitumor effect of pegylated liposomal doxorubicin
Yokoe I; Omata D; Unga J; Suzuki R; Maruyama K; Okamoto Y; Osaki T
Drug Deliv; 2021 Dec; 28(1):530-541. PubMed ID: 33685314
[TBL] [Abstract][Full Text] [Related]
10. Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.
Wang J; Qu H; Jin L; Zeng W; Qin L; Zhang F; Wei X; Lu W; Zhang C; Liang W
J Pharm Sci; 2011 Jun; 100(6):2267-77. PubMed ID: 21246559
[TBL] [Abstract][Full Text] [Related]
11. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
12. The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1--deficient ovarian tumors and can be exploited to improve treatment response in a mouse model.
Mantia-Smaldone G; Ronner L; Blair A; Gamerman V; Morse C; Orsulic S; Rubin S; Gimotty P; Adams S
Gynecol Oncol; 2014 Jun; 133(3):584-90. PubMed ID: 24680909
[TBL] [Abstract][Full Text] [Related]
13. Effects of Doxorubicin Delivery Systems and Mild Hyperthermia on Tissue Penetration in 3D Cell Culture Models of Ovarian Cancer Residual Disease.
Eetezadi S; De Souza R; Vythilingam M; Lessa Cataldi R; Allen C
Mol Pharm; 2015 Nov; 12(11):3973-85. PubMed ID: 26394060
[TBL] [Abstract][Full Text] [Related]
14. Improving anti-tumour efficacy of PEGylated liposomal doxorubicin by dual targeting of tumour cells and tumour endothelial cells using anti-p32 CGKRK peptide.
Mashreghi M; Faal Maleki M; Karimi M; Kalalinia F; Badiee A; Jaafari MR
J Drug Target; 2021 Jul; 29(6):617-630. PubMed ID: 33393376
[TBL] [Abstract][Full Text] [Related]
15. Intraductally administered pegylated liposomal doxorubicin reduces mammary stem cell function in the mammary gland but in the long term, induces malignant tumors.
Chun YS; Yoshida T; Mori T; Huso DL; Zhang Z; Stearns V; Perkins B; Jones RJ; Sukumar S
Breast Cancer Res Treat; 2012 Aug; 135(1):201-8. PubMed ID: 22752247
[TBL] [Abstract][Full Text] [Related]
16. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
Krishna R; Mayer LD
Cancer Res; 1997 Dec; 57(23):5246-53. PubMed ID: 9393743
[TBL] [Abstract][Full Text] [Related]
17. Selection and optimization of nano-formulation of P-glycoprotein inhibitor for reversal of doxorubicin resistance in COLO205 cells.
Dash TK; Konkimalla VSB
J Pharm Pharmacol; 2017 Jul; 69(7):834-843. PubMed ID: 28397291
[TBL] [Abstract][Full Text] [Related]
18. New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.
Gabizon AA; Patil Y; La-Beck NM
Drug Resist Updat; 2016 Nov; 29():90-106. PubMed ID: 27912846
[TBL] [Abstract][Full Text] [Related]
19. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
[TBL] [Abstract][Full Text] [Related]
20. Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts.
Gazzano E; Buondonno I; Marengo A; Rolando B; Chegaev K; Kopecka J; Saponara S; Sorge M; Hattinger CM; Gasco A; Fruttero R; Brancaccio M; Serra M; Stella B; Fattal E; Arpicco S; Riganti C
Cancer Lett; 2019 Aug; 456():29-39. PubMed ID: 31047947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]